Iron Status in Female Infertility and Recurrent Miscarriage
Launched by MEDICAL UNIVERSITY OF VIENNA · Aug 28, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the relationship between iron levels in the body and issues related to female fertility, specifically looking at women who have trouble getting pregnant or who have experienced multiple miscarriages. Researchers believe that having enough iron might be important for a woman’s ability to conceive and maintain a pregnancy. To explore this, the study will compare women with infertility and those with recurrent miscarriages to a group of healthy women who do not have these issues.
Eligible participants include women aged 18 to 40 who either have infertility defined as not being able to conceive after a year of trying, or who have experienced three or more miscarriages before the 20th week of pregnancy. Healthy women in the same age range, who do not have any fertility issues, can also join as a control group. All participants will need to provide their consent after receiving detailed information about the study. Those with certain health conditions, like inflammatory bowel disease or polycystic ovary syndrome, will not be eligible. Participants can expect to have their iron levels thoroughly evaluated as part of the study.
Gender
FEMALE
Eligibility criteria
- • Women with infertility
- Inclusion criteria:
- • The patient suffers from primary or secondary infertility, defined as the inability to conceive despite frequent unprotected sexual intercourse for at least 12 months.
- • The patient has given her written informed consent after detailed information on the study by medical professionals at the Department of Obstetrics and Gynecology of the Medical University of Vienna.
- • The patient is \>18 and \<40 years old.
- Exclusion criteria:
- • Inflammatoric bowel disease, cardiac insufficiency, chronic kidney disease, any malignant diseases.
- • Polycystic ovary syndrome.
- • There is no "informed consent".
- • Women with recurrent miscarriage
- Inclusion criteria:
- • The patient suffers from recurrent miscarriage, defined as three or more consecutive miscarriages before the 20th gestation week with the same partner.
- • The patient has given her written informed consent after detailed information on the study by medical professionals at the Department of Obstetrics and Gynecology of the Medical University of Vienna.
- • The patient is \>18 and \<40 years old.
- Exclusion criteria:
- • Inflammatoric bowel disease, cardiac insufficiency, chronic kidney disease, any malignant diseases.
- • Polycystic ovary syndrome
- • There is no "informed consent".
- • Healthy controls
- Inclusion criteria:
- • The woman does neither suffer from infertility/sterility nor from recurrent miscarriage and is also otherwise healthy with regular cycles.
- • The patient has given her written informed consent after detailed information on the study by medical professionals at the Department of Obstetrics and Gynecology of the Medical University of Vienna.
- • The patient is \>18 and \<40 years old.
- Exclusion criteria:
- • Inflammatoric bowel disease, cardiac insufficiency, chronic kidney disease, any malignant diseases.
- • Polycystic ovary syndrome
- • There is no "informed consent".
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Johannes Ott, MD, PhD
Principal Investigator
Medical University of Vienna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials